XTX Topco Ltd Buys 506,732 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Key Points

• XTX Topco Ltd significantly increased its holdings in Ironwood Pharmaceuticals by 1,104.4% in Q1, acquiring over 506,000 additional shares, bringing its total to approximately 552,613 shares valued at $812,000.
• Ironwood Pharmaceuticals recently reported a loss of $0.14 EPS for the quarter, missing the consensus estimate, with revenues of $41.14 million compared to a forecast of $67.02 million.
• Analyst ratings are mixed, with seven analysts giving a "hold" rating and two a "buy" rating, while the average price target for the stock is $4.78.

XTX Topco Ltd lifted its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 1,104.4% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 552,613 shares of the biotechnology company's stock after purchasing an additional 506,732 shares during the period. XTX Topco Ltd owned about 0.34% of Ironwood Pharmaceuticals worth $812,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IRWD. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $36,000. Simplicity Wealth LLC purchased a new position in Ironwood Pharmaceuticals during the first quarter worth $45,000. Envestnet Asset Management Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $50,000. Boothbay Fund Management LLC acquired a new position in Ironwood Pharmaceuticals in the 4th quarter worth $57,000. Finally, Y Intercept Hong Kong Ltd boosted its holdings in Ironwood Pharmaceuticals by 162.6% in the first quarter. Y Intercept Hong Kong Ltd now owns 39,782 shares of the biotechnology company's stock worth $58,000 after purchasing an additional 24,635 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wells Fargo & Company restated an "equal weight" rating and set a $1.00 target price (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Leerink Partners lowered their target price on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research note on Monday, April 14th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Craig Hallum cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 16th. Finally, Citizens Jmp downgraded shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a report on Monday, April 14th. Seven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $4.78.

Ironwood Pharmaceuticals Trading Up 12.8%

Shares of NASDAQ:IRWD traded up $0.10 on Thursday, reaching $0.91. The company had a trading volume of 4,626,575 shares, compared to its average volume of 2,938,077. Ironwood Pharmaceuticals, Inc. has a 52-week low of $0.53 and a 52-week high of $6.14. The firm's 50 day simple moving average is $0.72 and its 200-day simple moving average is $1.22. The firm has a market capitalization of $146.93 million, a PE ratio of -4.46 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. As a group, equities research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.